Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Vivesto AB stock logo
OASMY
Vivesto
$0.02
$0.02
$0.00
$0.02
$3.59M21.087 shsN/A
Otonomy, Inc. stock logo
OTIC
Otonomy
$0.01
$0.06
$0.01
$2.54
$582K1.54937,525 shsN/A
Veru Inc. stock logo
VERU
Veru
$1.31
+2.7%
$0.79
$0.36
$1.92
$191.76M-0.212.36 million shs677,393 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$1.75
-2.0%
$2.38
$1.46
$3.26
$245.09M2.332.14 million shs349,851 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Vivesto AB stock logo
OASMY
Vivesto
0.00%0.00%0.00%0.00%-60.00%
Otonomy, Inc. stock logo
OTIC
Otonomy
0.00%0.00%0.00%0.00%0.00%
Veru Inc. stock logo
VERU
Veru
+0.39%+1.59%+127.68%+199.37%-8.93%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
0.00%-1.11%-15.24%-24.58%-22.27%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Vivesto AB stock logo
OASMY
Vivesto
N/AN/AN/AN/AN/AN/AN/AN/A
Otonomy, Inc. stock logo
OTIC
Otonomy
N/AN/AN/AN/AN/AN/AN/AN/A
Veru Inc. stock logo
VERU
Veru
1.3295 of 5 stars
3.41.00.00.03.11.70.0
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
3.5951 of 5 stars
3.52.00.04.20.02.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Vivesto AB stock logo
OASMY
Vivesto
N/AN/AN/AN/A
Otonomy, Inc. stock logo
OTIC
Otonomy
N/AN/AN/AN/A
Veru Inc. stock logo
VERU
Veru
2.75
Moderate Buy$3.33154.45% Upside
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
3.00
Buy$4.88179.37% Upside

Current Analyst Ratings

Latest OTIC, OASMY, XERS, and VERU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Veru Inc. stock logo
VERU
Veru
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$7.00 ➝ $5.00
3/28/2024
Veru Inc. stock logo
VERU
Veru
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$3.00
3/28/2024
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$5.00
3/7/2024
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.50 ➝ $6.00
2/8/2024
Veru Inc. stock logo
VERU
Veru
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$2.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Vivesto AB stock logo
OASMY
Vivesto
$100K35.87N/AN/A$0.18 per share0.11
Otonomy, Inc. stock logo
OTIC
Otonomy
$130K4.48N/AN/A$0.97 per share0.01
Veru Inc. stock logo
VERU
Veru
$15.93M12.04N/AN/A$0.22 per share5.95
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$163.91M1.50N/AN/A($0.05) per share-34.90

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Vivesto AB stock logo
OASMY
Vivesto
-$35.35MN/A0.00N/AN/A-99.73%-91.27%N/A
Otonomy, Inc. stock logo
OTIC
Otonomy
-$51.18M-$0.77N/AN/AN/A-137.86%-68.50%N/A
Veru Inc. stock logo
VERU
Veru
-$93.15M-$0.75N/AN/AN/A-405.04%-257.92%-107.27%5/9/2024 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$62.26M-$0.45N/AN/AN/A-37.98%-610.76%-19.15%5/14/2024 (Estimated)

Latest OTIC, OASMY, XERS, and VERU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/1/2024Q1 2024
Veru Inc. stock logo
VERU
Veru
N/A-$0.09-$0.09-$0.10N/A$2.14 million
3/6/2024Q4 2023
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.09-$0.10-$0.01-$0.10$45.50 million$44.39 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Vivesto AB stock logo
OASMY
Vivesto
N/AN/AN/AN/AN/A
Otonomy, Inc. stock logo
OTIC
Otonomy
N/AN/AN/AN/AN/A
Veru Inc. stock logo
VERU
Veru
N/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Vivesto AB stock logo
OASMY
Vivesto
0.01
4.65
4.65
Otonomy, Inc. stock logo
OTIC
Otonomy
N/A
1.74
1.74
Veru Inc. stock logo
VERU
Veru
N/A
3.21
2.79
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
49.27
1.64
1.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Vivesto AB stock logo
OASMY
Vivesto
N/A
Otonomy, Inc. stock logo
OTIC
Otonomy
41.23%
Veru Inc. stock logo
VERU
Veru
47.16%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
Vivesto AB stock logo
OASMY
Vivesto
N/A
Otonomy, Inc. stock logo
OTIC
Otonomy
1.09%
Veru Inc. stock logo
VERU
Veru
14.20%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
4.36%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Vivesto AB stock logo
OASMY
Vivesto
14179.35 millionN/ANot Optionable
Otonomy, Inc. stock logo
OTIC
Otonomy
5168.53 million67.78 millionOptionable
Veru Inc. stock logo
VERU
Veru
189146.38 million125.60 millionOptionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
377140.45 million134.33 millionOptionable

OTIC, OASMY, XERS, and VERU Headlines

SourceHeadline
Xeris Biopharma Holdings, Inc.s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutionsXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions
finance.yahoo.com - April 5 at 12:23 PM
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - April 3 at 6:23 PM
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 2 at 8:50 AM
Xeris Biopharma (NASDAQ:XERS) Now Covered by OppenheimerXeris Biopharma (NASDAQ:XERS) Now Covered by Oppenheimer
marketbeat.com - March 28 at 8:29 AM
Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 GrowthXeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 Growth
proactiveinvestors.com - March 18 at 9:49 PM
Heres What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual ResultsHere's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Results
finance.yahoo.com - March 9 at 1:59 PM
Xeris Biopharma (XERS) Q4 2023 Earnings Call TranscriptXeris Biopharma (XERS) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 8 at 7:43 PM
Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023
finance.yahoo.com - March 7 at 2:41 PM
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call TranscriptXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript
insidermonkey.com - March 7 at 1:01 PM
Q4 2023 Xeris Biopharma Holdings Inc Earnings CallQ4 2023 Xeris Biopharma Holdings Inc Earnings Call
finance.yahoo.com - March 7 at 12:19 AM
Xeris Biopharma Shares Drop After Weak 4Q ResultsXeris Biopharma Shares Drop After Weak 4Q Results
marketwatch.com - March 6 at 7:18 PM
Xeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84MXeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84M
msn.com - March 6 at 7:18 PM
XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023
investorplace.com - March 6 at 2:00 PM
Xeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jumpXeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jump
proactiveinvestors.com - March 6 at 9:57 AM
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue EstimatesXeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
zacks.com - March 6 at 9:16 AM
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent EventsXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
businesswire.com - March 6 at 7:02 AM
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin CapitalXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
businesswire.com - March 6 at 7:00 AM
Why Xeris (XERS) Might Surprise This Earnings SeasonWhy Xeris (XERS) Might Surprise This Earnings Season
zacks.com - March 5 at 10:46 AM
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
businesswire.com - February 28 at 7:00 AM
3 Breakout Stocks Under $5 to Buy for More Upside3 Breakout Stocks Under $5 to Buy for More Upside
theglobeandmail.com - February 23 at 7:13 PM
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science ConferenceXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
finance.yahoo.com - February 5 at 9:27 AM
Big Game or Small, Heres How to Go About Stalking a TradeBig Game or Small, Here's How to Go About Stalking a Trade
realmoney.thestreet.com - February 3 at 6:45 PM
Xeris inks licensing deal with Amgen on former Horizon drugXeris inks licensing deal with Amgen on former Horizon drug
chicagobusiness.com - January 12 at 9:32 AM
Xeris Biopharma jumps on news of Amgen dealXeris Biopharma jumps on news of Amgen deal
thepharmaletter.com - January 12 at 9:32 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Vivesto logo

Vivesto

OTCMKTS:OASMY
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
Otonomy logo

Otonomy

NASDAQ:OTIC
Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.
Veru logo

Veru

NASDAQ:VERU
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Xeris Biopharma logo

Xeris Biopharma

NASDAQ:XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.